Key Points
- CEO Herriot Tabuteau sold 45,004 Axsome Therapeutics shares for approximately $9.54 million at an average price of $212.01, reducing his position by 86.16% to 7,229 shares.
- Axsome shares opened at $212.74, below their 50-day moving average of $236.95 but above their 200-day average of $203.96; the stock has traded between $102.67 and $260.19 over the past year.
- Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $265.55, while institutional investors own 81.49% of the company.
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) CEO Herriot Tabuteau sold 4,660 shares of the business's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $213.95, for a total transaction of $997,007.00. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company's stock, valued at approximately $1,546,644.55. The trade was a 39.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.
Herriot Tabuteau also recently made the following trade(s):
- On Wednesday, August 5th, Herriot Tabuteau sold 45,004 shares of Axsome Therapeutics stock. The shares were sold at an average price of $212.01, for a total transaction of $9,541,298.04.
- On Wednesday, July 1st, Herriot Tabuteau sold 49,666 shares of Axsome Therapeutics stock. The stock was sold at an average price of $240.25, for a total transaction of $11,932,256.50.
- On Tuesday, June 9th, Herriot Tabuteau sold 49,670 shares of Axsome Therapeutics stock. The stock was sold at an average price of $241.01, for a total transaction of $11,970,966.70.
Axsome Therapeutics Price Performance
Shares of Axsome Therapeutics stock opened at $212.74 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.39 and a debt-to-equity ratio of 2.27. The stock has a market capitalization of $10.95 billion, a price-to-earnings ratio of -57.03 and a beta of 0.65. Axsome Therapeutics, Inc. has a twelve month low of $102.67 and a twelve month high of $260.19. The company has a 50-day simple moving average of $236.95 and a two-hundred day simple moving average of $203.96.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC lifted their price target on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company a "buy" rating in a research report on Tuesday, May 5th. Cantor Fitzgerald reissued an "overweight" rating and set a $272.00 price target on shares of Axsome Therapeutics in a research report on Monday, May 4th. Royal Bank Of Canada lifted their price objective on Axsome Therapeutics from $302.00 to $304.00 and gave the company an "outperform" rating in a report on Tuesday, July 7th. Wells Fargo & Company raised their target price on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company an "overweight" rating in a report on Tuesday, May 5th. Finally, Jefferies Financial Group restated a "buy" rating and set a $380.00 target price on shares of Axsome Therapeutics in a research note on Thursday, June 11th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Axsome Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $265.55.
View Our Latest Stock Analysis on AXSM
Institutional Investors Weigh In On Axsome Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Kemnay Advisory Services Inc. acquired a new position in Axsome Therapeutics during the 4th quarter worth approximately $31,000. Hollencrest Capital Management boosted its position in Axsome Therapeutics by 400.0% in the first quarter. Hollencrest Capital Management now owns 200 shares of the company's stock valued at $34,000 after buying an additional 160 shares in the last quarter. Ameriflex Group Inc. acquired a new stake in Axsome Therapeutics in the fourth quarter valued at approximately $37,000. Advisory Services Network LLC bought a new stake in shares of Axsome Therapeutics during the third quarter worth $40,000. Finally, Farther Finance Advisors LLC grew its stake in shares of Axsome Therapeutics by 602.6% during the fourth quarter. Farther Finance Advisors LLC now owns 274 shares of the company's stock worth $50,000 after buying an additional 235 shares during the last quarter. 81.49% of the stock is owned by institutional investors.
Axsome Therapeutics Company Profile
(
Get Free Report)
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome's pipeline includes several late-stage and approved product candidates.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
